newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

LP352 Phase 1b/2a PACIFIC Study enrollment completed in August 2023 with topline data on track for January 2024 LP659 first-in-human Phase 1 single-ascending dose (SAD) study initiation expected Q4 2023, with